This review proposes that K2's superior adverse outcome occurrence is thanks, at least in part, to unique JWH-018 metabolite activity for the cannabinoid one receptor (CB1R), and suggests that metabolites of most medications, although not the carboxy metabolite, retain in vitro As well as in vivo activity at CB1Rs. The https://andresphwlz.daneblogger.com/30499668/am-2201-options